Featured News
New Molecular Testing for RSV now offers Higher Sensitivity
To meet the needs of elderly patients, who exhibit lower viral loads of RSV, Aculabs now offers a molecular assay. Respiratory syncytial virus
Aculabs utilizes rapid flu kits to help long-term care providers meet testing demands during flu season
Aculabs offers clients access to purchase CLIA-waived rapid flu testing kits, with each kit priced at $325 (subject to tax and credit
Aculabs celebrates 50 years dedicated to service with integrity
This week of September 12th, Aculabs officially celebrates its 50th anniversary in operations, and Dauna Gudaitis, our corporate secretary, and the company's
Henry Schein Extends Expiration Date on One Step Ultra Flu Test
Please be aware Henry Schein has extended the expiration date for its ONE STEP ULTRA FLU TEST 25/Bx A/B Test (manufacturer product
Healthcare providers urge Congress to Replenish the HRSA Uninsured Relief Fund
Led by the American Clinical Laboratory Association (ACLA), over 60 public health organizations representing patients, health care professionals, hospitals, public health, laboratories, and
Aculabs rolls out updates to Online Order web portal tools
The start of 2022 saw Aculabs roll out several new features to our online web portal, including Email Reporting for Result Notification
QuantiFERON-TB Gold Plus now performed as in-house testing
Aculabs will be offering QuantiFERON-TB Gold Plus in-house as of April 6, 2022; the test provides highly accurate and reproducible results, single-step
Supply Shortage on Grey & Pink Para-Paks to Impact Testing
Please be aware that several send-out tests will be temporarily unavailable to order, as supply shortages impacting the grey and pink parapak
New Updates to Aculabs Online Order Entry System
As an industry leader, Aculabs values the way in which our digital and technological systems can always be improved to continually optimize
FDA Warns of Reduced Sensitivity for Omicron in Rapid Tests
In a new memo, the United States Food & Drug Administration (FDA) has documented and warned both patients and healthcare providers of